

## MAYNE PHARMA GROUP LIMITED

# COMMUNICATIONS POLICY

### 1. Introduction

The Board of Directors of Mayne Pharma Group Limited ("Mayne Pharma" or "Company") has established the Communications Policy to promote effective communications with shareholders and stakeholders.

The Shareholder Communications Policy endorses the Australian Securities Exchange (ASX) Corporate Governance Council's Corporate Governance Principles and Recommendations (3rd Edition).

### 2. Responsible Persons

Mayne Pharma engages with the investment community through the Company's Chairman, CEO, Group CFO and other senior executives.

### 3. Methods of Shareholder Engagement

#### 3.1 ASX Release

In the first instance, the Company will release all information to the public through an ASX release. The Company will ensure the release complies with the Company's Continuous Disclosure Policy.

The Board is responsible for approving all significant planned disclosures to be made to the ASX (such as announcements of financial results, market guidance or major transactions). In the event that the Company needs to make a significant announcement of an urgent or unscheduled nature in order to meet its reporting obligations under the Corporations Act and the ASX Listing Rules, and it is impractical for the Board to be convened, the Chairman is authorised to approve the form and substance of such a disclosure.

#### 3.2 Website

Mayne Pharma's website ([www.maynepharma.com](http://www.maynepharma.com)) will be updated on a regular basis and contain information including:

- History and operations of Mayne Pharma;
- Background on Mayne Pharma's board and senior management;
- The Company's corporate governance statement and policies; and
- ASX announcements.

ASX announcements will be posted on the Mayne Pharma website as soon as practicable following confirmation of receipt by the ASX.

#### 3.3 Annual Report

Mayne Pharma's Annual Report is released to the ASX and made available on Mayne Pharma's website. Hard copies are mailed to shareholders on request. The Company will use the Annual Report to summarise and inform shareholders of the Company's operations and financial performance for the previous year.

### **3.4 Annual General Meeting (AGM)**

Through the Notice of Meeting, the Company will encourage all shareholders and other interested parties to attend the AGM as it will give them an opportunity to ask questions and meet key personnel. An update of the Company's activities will also be provided through a presentation at the AGM. The Chairman and CEO's addresses and voting results are released to the ASX and available on the Company's website. All shareholders who are unable to attend these meetings are encouraged to communicate or ask questions by writing to the Company.

The Company's auditor will be requested to attend the AGM and be available to answer shareholder questions about the conduct of the audit and the preparation and content of the auditor's report.

### **3.5 Direct Communication and Presentations**

Shareholders, stakeholders and other interested parties are welcome to contact the CEO, Group CFO and Company Secretary or Investor Relations Manager directly. The Company will also be available to provide presentations to investor groups, brokers, institutions, media and industry-related parties on a regular basis. Where possible, the Company will accept invitations to publicly present on the Company at relevant seminars and conferences. At all times information released to any of the parties must conform to the Continuous Disclosure Policy.

### **3.6 Media**

Key information released to the ASX will also be forwarded to relevant media organisations. The Company will also pursue and encourage publicity on the Company through feature articles and briefings. The Company is also willing to accept invitations from the media to make comment on industry-related activities unless there is good reason for not doing so. All media contact must be authorised by the Chief Executive Officer.

## **4. Contacts**

Contact details for the Company are:

Mayne Pharma Group Limited  
1538 Main North Road  
Salisbury South, SA 5106  
Australia

Phone: +61 8 8209 2666

Fax: +61 8 8281 6998

Website: [www.maynepharma.com](http://www.maynepharma.com)